Leerink analyst Joseph Schwartz says there were no "major surprises" at the Peripheral and Central Nervous System Drugs Advisory Committee panel, which voted against Sarepta's eteplirsen for the treatment of Duchenne muscular dystrophy. The FDA remained focused on the scientific merit of objective data, however scarce, the analyst tells investors in a research note, adding that he assumes a 40% probability of eteplirsen approval and commercial success. Schwartz notes that the ultimate FDA decision is expected on May 26. The analyst reiterates a Market Perform rating and $13 price target on the shares.